Abstract
Cefpirome (CPR), a new injectable cephem antibiotic, was administered in the treatment of 39 cases of urological infection.
For the 36 cases evaluated, we obtained the following results.
1. In complicated UTI, as assessed by the criteria of the Japanese UTI Committee, the clinical efficacy rate was 61.1%(11/18).
2. In complicated UTI, evaluated by the doctors in charge, it was 52.2%(11/23).
3. In urethritis it was 100%(2/2).
4. In prostatitis it was 100%(11/11).
No subjective adverse reactions were observed, but in laboratory findings transient elevations of monocytes, eosinophilic leucocytes and GOT and GPT were observed in six cases.
